Premium
PIII‐43
Author(s) -
Tian J.
Publication year - 2006
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.12.251
Subject(s) - triglyceride , medicine , blood pressure , insulin , endocrinology , lipoprotein , carbohydrate metabolism , cholesterol , low density lipoprotein , chemistry
BACKGROUND This study evaluated the effect of hydroxysafflor yellow A (HSYA) monotherapy on blood pressure and metabolic changes. METHODS Various aspect of carbohydrate and lipoprotein metabolism were studied before and after 12 weeks of HSYA treatment in 23 patients with mild to moderate essential hypertension. RESULTS HSYA was well tolerated and induced a significant decrease ( P <0.001) in both systolic and diastolic blood pressure without any changes in heart rate. Plasma levels of fasting glucose, insulin, C‐peptide and hemoglobin A1c, hepatic extraction of insulin were similar following HSYA treatment. Plasma glucose and insulin responses to an oral glucose challenge did not change in association with HSYA therapy. Although high density lipoprotein cholesterol concentration increased slightly, it did not reach statistical significance. Total cholesterol and low density lipoprotein cholesterol levels also increased insignificantly. LDL triglyceride and very low density lipoprotein triglyceride concentrations were higher marginally, which resulted in slightly but insignificantly increase in total triglyceride concentration in association with HSYA monotherapy for 12 weeks. CONCLUSION Treatment of patients with mild to moderate hypertension with HSYA led to lower blood pressure effectively while had no significant influence on carbohydrate and lipoprotein metabolism. Clinical Pharmacology & Therapeutics (2005) 79 , P69–P69; doi: 10.1016/j.clpt.2005.12.251